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Abstract
Objective: U-74006F is the only Lazaroid which is currently in clinical use. A number of experimental studies demonstrate that
Lazaroids reduce ischemia/reperfusion injury in various organ systems. We evaluated the effect of U-74006F on reperfusion injury in a
large animal model of lung allo-transplantation. Methods: Two different treatment modalities were evaluated and compared with corre-
sponding control groups. Unilateral left lung transplantation was performed in 21 weight-matched pigs (24–31 kg). Donor lungs were
flushed with 1.5 l cold (1 ° C) LPD solution and preserved for 20 h. In group I (n = 5), donor animals were pretreated with U-74006F (10 mg/
kg i.v.) 20 min before harvest. In addition U-74006F was added to the flush solution (10 mg/l). In group III (n = 6), the Lazaroid was given
to the donor before flush and to the recipient before reperfusion (3 mg/kg i.v.). Group II and IV (n = 5) served as control. One hour after
reperfusion, the recipient contralateral right pulmonary artery and bronchus were ligated to assess graft function only. Extravascular lung
water index (EVLWI), mean pulmonary artery pressure, cardiac output, and gas exchange were assessed during a 5 h observation period.
Lipid peroxidation (TBARS) and neutrophil migration (MPO activity) were measured at the end of the assessment in lung allograft tissue.
Results: A significant change of TBARS concentration was shown in group III (group III 78.7 – 4.6 pmol/g vs. group IV 120.8 – 7.2 pmol/
g (P = 0.0065) normal lung tissue 41.3 – 4.2 pmol/g). MPO activity was reduced in group III 3.74 – 0.25 DOD/mg per min vs. group IV
4.97 – 0.26 DOD/mg per min (P = 0.027), normal lung tissue 1.04 – 0.27 DOD/mg per min). Pulmonary hemodynamics and gas exchange
after reperfusion did not differ between groups. In group I and III, a tendency towards a reduced EVLWI was noted. Conclusion: We
conclude that combined treatment of donor and recipient with U-74006F reduces free radical mediated injury in the allograft. However, this
intervention did not result in a significant reduction of post-transplant lung edema or improvement of pulmonary hemodynamics. Donor
pretreatment alone did not improve lung allograft reperfusion injury. These results indicate that the benefit of U-74006F is too small to
consider clinical application in lung transplantation. Ó 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
During the last 10 years, lung transplantation has become
an accepted treatment modality for patients with end stage
lung disease. Despite improved organ preservation and peri-
operative management, graft dysfunction remains a signifi-
cant and unpredictable clinical problem and occurs in a
severe form in over 10% of the recipients.
Activation of humoral and cellular responses are thought
to be crucial for the development of post-transplant reper-
fusion injury. Important mediators include neutrophil
granulocytes, the complement system and oxygen free radi-
cals.
Lazaroids are a group of 21-aminosteroids, which were
originally synthesized as inhibitors of lipid peroxidation
after trauma, bleeding, or ischemia of the CNS. They reduce
lipid peroxidation [1,2] and subsequent edema formation
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[3,4] in combination with minimal glucocorticoid- or immu-
nosuppressive side effects [5]. The protective capacity of
these compounds made them candidates for use in other
systems, e.g. post-transplant ischemia/reperfusion. A num-
ber of in vivo and ex vivo experiments of ischemia/reperfu-
sion injury using different Lazaroid compounds were
published with contradictory results [6,7].
However, because of unfavorable pharmacodynamic and
pharmacokinetic properties such as toxicity and instability
of other Lazaroids [2], U-74006F is still the only substance
of this group in clinical use. The purpose of this study was to
evaluate the effect of U-74006F on post-transplant reperfu-
sion injury using two different treatment modalities – donor
pretreatment alone and combined donor/recipient treatment
– in a large animal model of unilateral lung transplantation
following prolonged preservation.
2. Materials and methods
2.1. Animals and operative procedure
Twenty-one weight-matched pairs of outbreed pigs
served as donors and recipients. Harvest and left lung trans-
plantation were performed as previously reported [8].
2.2. Study groups
In group I (n = 5) donor animals were pretreated with the
21-aminosteroid U-74006F (Freedox Ò , generously provided
by Pharmacia Upjohn AG, Du¨bendorf, Switzerland) 20 min
before flush in a dose of 10 mg/kg i.v. over 10 min. In
addition U-74006F was added to the low potassium dextran
(LPD) solution (Perfadex Ò , generously provided by Upjohn/
Medisan Pharmaceuticals AB, Uppsala, Sweden) in a dose
of 10 mg/l. In group III (n = 6), the Lazaroid was given to
the donor before flush and to the recipient before reperfu-
sion (3 mg/kg i.v.). Group II and IV (n = 5) served as con-
trol, no 21-aminosteroid was administered. The total
preservation time was 20 h in all groups. In group I and
II, the transplantation was performed after 18 h of cold
ischemia (1 ° C) and a 2 h period of warm ischemia (20 ° C).
In this first series of experiments, donor preparation and
implantation were performed without topical cooling of
the graft. In groups III and IV, the grafts were cooled topi-
cally with ice slush during dissection and implantation to
prevent warm ischemia as in clinical practice. U-74006F
was administered according to the manufacturers instruc-
tions based on toxicity and pharmacological characteristics.
All animals received humane care in compliance with the
European Convention on Animal Care. The protocol was
approved by the local animals study committee.
2.3. Assessment
One hour after reperfusion of the transplanted lung, the
right pulmonary artery and the right main bronchus were
ligated to assess allograft function only. During the assess-
ment period anesthesia was maintained with Fluothane
1.5%. Systemic arterial, pulmonal arterial, central venous
and left atrial pressure were recorded continuously. Arterial
and mixed venous blood were collected for gas analysis
every 60 min.
At the end of the assessment period, 5 h after reperfusion,
the animals were sacrificed. Upper lobe allograft samples
were submitted to histologic examination and tissue MPO
and TBARS assay.
2.4. Extravascular lung water
Extravascular lung water as direct assessment of reperfu-
sion edema was measured as previously described [8].
A fiberoptic catheter (System Cold Z-021, Pulsion,
Munich, Germany) is advanced via the external carotid
artery into the descending aorta. The indicator bolus con-
sists of two components. Indocyanine green serves as intra-
vascular marker and ice cold 5% glucose as a thermal intra-
and extravascular indicator. The bolus is injected via the
external jugular vein with a temperature controlled injector.
The dilution curves for dye and temperature are recorded
simultaneously in the descending aorta with the thermistor
tipped fiberoptic catheter. Thoracic intravascular and extra-
vascular fluid volumes are determined based on the mea-
surement of the mean transit times for thermal and dye
indicators and of the decay time volumes calculated from
the indicator dilution curves as described previously [9].
The lung water computer (System Cold Z-021, Pulsion,
Munich, Germany) determines the mean transit time for
the thermal indicator and for the dye indicator and calcu-
lates total thermal volume (ITTV), intrathoracic blood
volume (ITBV), and extravascular thermal volume (ETV)
[10]. The extravascular thermal volume (ETV) is calculated
as follows: ETV = ITTV - ITBV. All measurements were
made hourly in triplicate. The mean value was used for
analysis.
2.5. Myeloperoxidase assay
Donor and recipient lung samples were frozen immedi-
ately and stored at - 70 ° C until assay. Quantitative MPO
activity was determined as previously described [11].
Enzyme activity is expressed as the change in optical den-
sity unit per milligram of tissue protein per minute (DOD/
mg per min).
2.6. TBARS assays
The thiobarbituric acid-reactive substance (TBARS)
levels in lung tissue were measured according to the method
of Ohkawa et al. [12] with 10% wet weight per volume
homogenate. TBARS levels were determined by reference
to a standard curve of 1,1,3,3-tetramethoxypropane (Sigma
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Chemicals, Buchs, Switzerland), and the results were
expressed as picomoles of malondialdehyde (MDA)/g of
wet lung.
2.7. Statistical analysis
All values are given as the mean – standard error of the
mean (SEM). Donor weight, recipient weight, total preser-
vation time, warm ischemic time, TBARS assay and MPO
assay were checked for normal distribution within groups
and analyzed by unpaired t-test. Gas exchange, hemody-
namic parameters and extravascular lung water were
assessed by repeated measures ANOVA and planned com-
parison was applied. Analysis was performed by ANOVA
(StatView 4.5, Abacus Concepts, 1995). P-values less than
0.05 were considered significant.
3. Results
3.1. Characteristics of experimental groups
No statistical differences between groups (I vs. II and III
vs. IV) were noted in donor weight, recipient weight, total
preservation time and warm ischemic time (Table 1).
3.2. Reperfusion edema
At the end of the 5 h assessment period, only a tendency
towards a reduced allograft reperfusion edema in compar-
ison with the controls was noted (group I 5.2 – 0.2 ml/kg vs.
group II 6.7 – 1.1 ml/kg, P = 0.16, and group III 7.4 – 0.6
ml/kg vs. group IV 9.2 – 0.9 ml/kg, P = 0.13) (Fig. 1).
3.3. Gas exchange
PaO2 levels in the Lazaroid treated animals were higher at
the end of the 5 h assessment period (group I 73.52 – 2.30
kPa vs. group II 69.05 – 1.61 kPa and group III 74.8 – 2.1
kPa vs. group IV 61.7 – 7.6 kPa), but statistical analysis did
not demonstrate a significant difference between groups.
3.4. Hemodynamic parameters
No statistically significant difference between groups was
noted in cardiac output (group I 2.5 – 0.3 l/min vs. group II
3.1 – 0.2 l/min and group III 3.6 – 0.2 l/min vs. group IV
3.1 – 0.4 l/min), pulmonary vascular resistance (group I
638 – 41 dynes/s per cm - 5 vs. group II 571 – 62 dynes/s
per cm - 5 and group III 528 – 82 dynes/s per cm - 5 vs. group
IV 580 – 85 dynes/s per cm - 5) and pulmonary arterial pres-
sure (group I 27 – 1 mmHg vs. group II 30 – 1 mmHg and
group III 31 – 1 mmHg vs. group IV 32 – 3 mmHg) during
the 5 h assessment period (Fig. 2).
3.5. PMN migration
Allograft MPO activity was reduced in group III animals
in comparison with the corresponding control group (group
I 3.78 – 0.30 DOD/mg per min vs. group II 3.25 – 0.37
DOD/mg per min and group III 3.74 – 0.25 DOD/mg per
min vs. group IV 4.97 – 0.26 DOD/mg per min, (P = 0.027).
MPO activity in normal unflushed lung tissue was
1.04 – 0.27 DOD/mg per min (Fig. 3).
3.6. TBARS
The malondialdehyde concentration as expression for
lipid peroxidation was significantly reduced in group III
(group I 126.9 – 15.9 pmol MDA/g vs. group II 120.8 –
11.8 pmol MDA/g and group III 78.7 – 4.6 pmol MDA/g
vs. group IV 120.8 – 7.2 pmol MDA/g, normal lung tissue
41.3 – 4.2 pmol MDA/g) (P = 0.0065) (Fig. 3).
4. Discussion
A number of mechanisms of the non-specific immune
system mediate lung allograft ischemia/reperfusion injury.
This acute lung injury manifests as post-transplant lung
edema with subsequent increase of pulmonary vascular
resistance and reduced gas exchange. One of the most
important mediators of ischemia/reperfusion injury are
superoxide radicals, which are generated during preserva-
tion and reperfusion. Oxygen free radicals damage mem-
branes and organelles by forming lipid peroxides which
alter the configuration and function of these structures.
Lazaroid molecules act as membrane stabilizers by sol-
ving in the lipid bilayer of cell membranes with the hydro-
phobic steroid moiety located in the lipid phase and the
Table 1
Characteristics of experimental groups
Group (treatment) I (Donor) II (Control) III (Donor + Recipient) IV (Control)
Donor weight (kg) 26.2 – 0.78 28.2 – 1.27 27.2 – 1.1 27.1 – 1.2
Recipient weight (kg) 25.5 – 0.55 27.8 – 1.27 26.5 – 0.6 27.6 – 2.3
Total preservation time (min) 1221 – 11 1215 – 16 1180 – 3 1218 – 16
Warm ischemic time (min) 146 – 7 148 – 7 44 – 5 46 – 4
No statistical differences were noted in donor weight, recipient weight, total preservation time and warm ischemic time between the corresponding groups.
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more hydrophilic heterocyclic ring system near the phos-
pholipid head groups [13]. In addition, Lazaroids are known
to act as potent free radical scavengers [2].
In experimental and clinical studies, a beneficial effect of
Lazaroids after neuro trauma has been demonstrated [1–4].
In the field of organ preservation, a considerable amount of
work has been done to evaluate the effects of Lazaroids with
contradictory results.
Salahudeen et al. noted that renal function improved with
U-74006F treatment after transplantation in rats. This effect
correlated with a decrease of plasma and tissue MDA levels
[14]. In contrast, Ishizaki and Wang found no significant
changes in lipid peroxidation with U-74006F, but they
observed a clear decrease with a definite dose of U-
74500A [6,13]. In a previous study reported by Killinger
et al., different Lazaroid compounds were compared. U-
74006F in contrast to U-74500A did not improve endothe-
lial cell viability [7]. U-74500A was found to be a more
potent inhibitor of iron-catalyzed lipid peroxidation than
U-74006F, but this compound has not been further devel-
oped due to pharmaceutical instability and rapid elimination
in vivo [2]. The two most important reasons for the decision
to choose U-74006F for clinical application were the low
toxicity and the best solubility in clinically applicable sol-
vents (E. Hall, personal communication).
Lipid peroxides stimulate cytokine production and induce
expression of adhesion with subsequent leucocyte activa-
tion and migration. Neutrophil activation highly correlates
with the severity of lung injury [15], and Lazaroids are
thought to reduce neutrophil migration after transplantation.
Palma-Vargas reported a decrease in MDA levels and neu-
trophil infiltration with U-74389G [16], but U-74006F did
not reliably reduce neutrophil tissue migration following
ischemia/reperfusion in vivo [17] and in vitro [18,19]. In
the experiments of Ishizaki, the neutrophil infiltration was
even higher in the U-74006F group in comparison with U-
74500A and U-74389G treated animals [6]. In the present
study, we registered a significant decrease of neutrophil
migration into the allograft after U-74006F administration
in the group with combined treatment of donor and recipient
(Fig. 3).
A number of authors previously evaluated the effect of
Lazaroids in lung transplantations. Tanoue et al. noted a
positive effect on pulmonary hemodynamics and gas
exchange with U-74500A-treatment in a canine single left
lung transplantation model [20]. Du et al. described similar
results in a partially in vivo rat transplant model [21]. A
favorable effect on gas exchange, however, could only be
detected after 12 h of cold ischemic storage. After a 6-h
preservation period, no difference between control and
Lazaroid treated groups was found. Furthermore, the lung
water content, which clearly raised after reperfusion, did not
differ between groups. In our experiments, we could only
demonstrate a tendency towards reduced lung edema with
both treatment modalities, and no improvements in hemo-
dynamic parameters nor gas exchange after Lazaroid treat-
ment were noted.
Several ways of Lazaroid administration are described in
the literature. It was added to the flush solution and/or to the
recipient at the time or shortly before reperfusion. However,
because the process of lipid peroxidation is thought to start
at the onset of ischemia and is accelerated during reperfu-
sion [22], we choose donor pretreatment before organ har-
vest as a reasonable way of administration in the first series
of experiments. Sasaki et al. evaluated donor in vivo admin-
Fig. 1. Extravascular lung water index (EVLWI) in the pulmonary allo-
graft in the control groups increased during the first 120 min after reperfu-
sion followed by a slight decrease. Lazaroid treatment did not reduce
EVLWI significantly (groups I and III).
Fig. 2. Pulmonary vascular resistance (PVR) increased at the time of
exclusion of the right native lung in all groups. Lazaroid treatment did
not reduce this increase.
Fig. 3. PMN migration (MPO activity) and thiobarbituric acid reactive
substance (TBARS) in lung allograft tissue at the end of the assessment.
A significant reduction of both parameters in comparison with the controls
could be demonstrated when the Lazaroid was given to the donor and the
recipient (group III).
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istration of Lazaroid U-74389G [23] and confirmed the
results of Lambert and Egan, which demonstrate that a
free radical scavenger must be present at the time of harvest
to be effective [24]. In the study of Hausen et al., in a rat
model of double-lung transplantation, donor treatment with
U-74389G was more effective than administration to the
recipient only [25]. The importance of treating the residual
neutrophil pool in the donor lung as well as preventing lipid
peroxidation caused by oxygen-free radicals released during
ischemia from donor endothelial cells are thought to be
important. Our results, however, indicate that donor treat-
ment alone with U-74006F is not sufficient.
In preliminary studies, we noted that after 20 h of cold
ischemic storage, donor treatment with U-74006F did not
ameliorate reperfusion injury in this model [26]. As it is
thought that oxygen free radicals are produced during
warm ischemia, we extended the warm ischemic period in
part one of the experiment (groups I and II) to 2 h before
implantation.
An ischemic time of 20 h was chosen in this experiment
to produce a severe reperfusion injury. Following this
ischemic damage, the animals still tolerate ligation of the
right pulmonary artery which allows to assess isolated graft
function. If a longer preservation period is used, a rapid
decrease of allograft gas exchange is noted and the animals
die from right heart failure. It could be hypothesized that an
ischemic time of 20 h is too long to demonstrate the protec-
tive effect of Lazaroids, however, other groups reported in a
canine model improved outcome after liver and lung trans-
plantation with even longer ischemic times [20,27].
We conclude that combined treatment of donor and reci-
pient with U-74006F, which is still the only clinically used
Lazaroid, reduces free radical mediated injury in the allo-
graft, however, this intervention did not improve neither
post-transplant lung edema nor pulmonary hemodynamics.
Donor pretreatment alone did not improve lung allograft
reperfusion injury. These results indicate that the benefit
of Lazaroids is too small to consider clinical application
in lung transplantation.
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